BioXcel Accounts Payable from 2010 to 2025
| BTAI Stock | USD 0.33 0.01 1.88% |
Accounts Payable | First Reported 2016-12-31 | Previous Quarter 13.3 M | Current Value 14.9 M | Quarterly Volatility 4.6 M |
Check BioXcel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioXcel Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 76.7 M or Total Revenue of 1.7 M, as well as many indicators such as Price To Sales Ratio of 68.03, Dividend Yield of 0.0 or Days Sales Outstanding of 20.52. BioXcel financial statements analysis is a perfect complement when working with BioXcel Therapeutics Valuation or Volatility modules.
BioXcel | Accounts Payable |
Latest BioXcel Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of BioXcel Therapeutics over the last few years. An accounting item on the balance sheet that represents BioXcel Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioXcel Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. BioXcel Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioXcel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
BioXcel Accounts Payable Regression Statistics
| Arithmetic Mean | 4,605,144 | |
| Geometric Mean | 1,431,915 | |
| Coefficient Of Variation | 129.77 | |
| Mean Deviation | 4,758,930 | |
| Median | 1,604,000 | |
| Standard Deviation | 5,975,913 | |
| Sample Variance | 35.7T | |
| Range | 16.2M | |
| R-Value | 0.87 | |
| Mean Square Error | 9.1T | |
| R-Squared | 0.76 | |
| Significance | 0.00001 | |
| Slope | 1,095,242 | |
| Total Sum of Squares | 535.7T |
BioXcel Accounts Payable History
About BioXcel Therapeutics Financial Statements
Investors use fundamental indicators, such as BioXcel Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Although BioXcel Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 15.7 M | 16.5 M |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out the analysis of BioXcel Therapeutics Correlation against competitors. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share | Quarterly Revenue Growth 1.416 | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.